Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc

Bullboard Posts

Post by cpacon Sep 05, 2019 12:16pm

371 Views

Post# 30098519

Extremely Encouraging Update

There are a number of upcoming catalysts.
Dr. Coffey reminded people why ONC's product is completely unique
ImmunoOncology is a breakthrough area of medicine, but there is still a low rate of success... maybe 1 in 5 who take these drugs?
If ONC's product can help prime the immune system to recognize these tumors and make IO drugs meaningfully more effective, what would that be worth?
Several billion dollars?
And there is every indication that it can do exactly that...
Current price makes no sense.... stock should be at $10 today and bumping higher as each new milestone is reached over the next year and a half...

Bullboard Posts

Advancing an underexplored area of the Yukon with the same geology as B.C’.s Golden Triangle